MRD-Guided PRaG 3.0 Therapy for HER-2 Positive Cervical Adenocarcinoma: A Case of Complete Remission

Advanced cervical adenocarcinoma with human epidermal growth factor receptor 2 (HER-2) expression poses significant treatment challenges. This case report explores the efficacy of PRaG 3.0 therapy, a novel combination of radiotherapy, immunotherapy agent granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and programmed death receptor 1 (PD-1) inhibitor, and disitamab vedotin (RC48), a targeted anti-HER2 antibody-drug conjugate. A patient with advanced, refractory cervical adenocarcinoma and HER-2 expression (immunohistochemistry 1 + ), underwent PRaG 3.0 therapy, resulting in complete tumor remission after two cycles, sustained over 16 additional cycles without significant side effects. Post-treatment, ctDNA and lymphocyte monitoring confirmed continued remission. In conclusion, PRaG 3.0 therapy demonstrates promising potential for managing complex cases of cervical adenocarcinoma.